CIPLA: LANREOTIDE RECALL DEEPENS US RISK; RESTART TIMELINE AT RISK

Cipla has initiated a complete Class II recall of its Lanreotide injection in the U.S., escalating quality concerns. Analysts warn of potential USFDA inquiry and legal action. Nomura notes Lanreotide is among Cipla’s largest U.S. products, with an estimated annual sales run-rate of USD 120–150 million; resupply in H1 FY27 now appears unlikely.